

ANDY GOREN
(USA)

Prof. Dr. Andy Goren has over 20 years of experience in research, development and commercialization of breakthrough therapeutics and diagnostics.

Among the list of many firsts in dermatology, Prof. Goren was the first to develop a clinical genetic test for predicting androgenetic alopecia, the first to discover epigenetic markers predicting anti-androgen therapy response in female androgenetic alopecia, the first to develop a clinical acne vulgaris antibiotic response test based on P. Acnes bacterial genomics, and the first to develop a rapid test for predicting minoxidil response in androgenetic alopecia.

Prof. Goren is actively involved in the development, commercialization, and listing of several drugs and medical devices including new therapies for female pattern hair loss, chemotherapy-induced alopecia, excessive hair shedding, and female sexual dysfunction. His latest research involves the development of dermatology therapies based on genetically modified organisms.

Prof. Goren currently serves as a Professor of Dermatology at the University of Rome "G.Marconi", Italy; a visiting Professor at the Department of Dermatology and Venereology, Clinical Hospital Center Sestre Milosrdnice in Zagreb, Croatia; a visiting Medical Doctor at the Department of Dermatology and Venereology, L.T.M. Medical College Sion in Mumbai, India; and the Global Medical Director of Hairmore Group in Beijing, China.

Prof. Goren has published dozens of manuscripts in dermatology. He is an honorary as well as an ordinary member of several dermatology societies worldwide as well as a regular lecturer at dermatology congresses around the world. He held numerous appearances and interviews on mainstream TV, radio, and prestigious newspapers.